Newsroom

New York, NY – April 21, 2017 – The Edison Awards, celebrating 30 years of honoring the best in innovation and excellence in the development of new products and services, announced today that Sera’ PreTRM Test was voted a Silver Winner for innovation in the “Health and Wellness” category at the April 20th event at The Capitale in New York City.

SALT LAKE CITY, March 13, 2017 — Research using Sera’s innovative proteomic technology platform that revealed evidence for fetal sex differences in placental gene expression as a possible explanation of the association of fetal gender and rate of preterm birth (PTB) will be presented at the 64th Annual Society for Reproductive Investigation March 15-18 in Orlando.

SALT LAKE CITY, February 9, 2017 – Sera has been named a 2017 Award Finalist by the internationally renowned Edison Awards™. These distinguished awards, inspired by Thomas Edison’s persistence and inventiveness, recognize leadership in innovation, creativity and ingenuity in the global economy.

January 23, 2017 — Presentations at SMFM of ongoing research will include evaluating the underlying mechanisms of significant pregnancy complications that result in preterm birth, use of progesterone as an intervention and employing Sera’s innovative proteomic technology platform to predict a woman’s risk for spontaneous and medically-indicated preterm birth.

SALT LAKE CITY, January 10, 2017– LabCorp Leads $40 Million Series C Financing as Sera Expands its Activities to Address Premature Birth. Sera, Inc., a woman’s healthcare company, announced today that it has entered into a strategic collaboration with Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), a world leading life sciences company, to be the exclusive U.S. distributor of Sera’s PreTRM® test. PreTRM is the first and only clinically-validated blood test that provides an early and individualized prediction of preterm birth risk.

SALT LAKE CITY, January 3, 2017 — Sera, Inc., a women’s healthcare company, today announced that Gregory C. Critchfield, M.D., M.S., Chairman and Chief Executive Officer, will present at the upcoming J.P. Morgan Healthcare Conference. Dr. Critchfield’s presentation will take place at 7:30 AM PT on Tuesday, January 10th, 2017 in the Elizabethan Room at the Westin St. Francis Hotel in San Francisco, CA.

December 19, 2016 – Two recent publications show significant clinical utility of assessing preterm birth risk early in pregnancy with novel biomarker tests such as PreTRM®. These reports describe treatment paradigms that use existing interventions with significant potential to improve the health of premature babies, including reduction in mortality rates, as well as a corresponding reduction of direct medical costs to the health care system.

November 21, 2016 – Sera, Inc., a women’s healthcare company, today announced that Gregory C. Critchfield, M.D., M.S., Chairman and Chief Executive Officer, will present at the upcoming 28th Annual Piper Jaffray Healthcare Conference. Dr. Critchfield’s presentation will take place at 11:30 AM ET on Tuesday, November 29th, at the Lotte New York Palace in New York.

September 20, 2016 – Sera, Inc., a women’s healthcare company, today announced that Gregory C. Critchfield, M.D., M.S., Chairman and Chief Executive Officer, will present at the upcoming Ladenburg Thalmann 2016 Healthcare Conference. Dr. Critchfield’s presentation will take place at 11:00 AM ET on Tuesday, September 27th, at the Sofitel Hotel in New York.

May 12, 2016 – Sera, Inc., a women’s health company, today announced that it was selected as the 2016 Utah Innovation Award winner in the Life Science – BioTech category for its novel PreTRM® test, a clinical blood test for early, individualized risk assessment of premature birth.